Cosmo Pharmaceuticals Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
347
- Stock Symbol
-
CMHC
- Investments
-
8
- Share Price
-
$68.42
- (As of Friday Closing)
Cosmo Pharmaceuticals General Information
Description
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
Contact Information
Website
www.cosmohealthconfidence.comCorporate Office
- 7th Floor, One North Dock
- 91/94 North Wall Quay
- Dublin D01 H7V7
- Ireland
Corporate Office
- 7th Floor, One North Dock
- 91/94 North Wall Quay
- Dublin D01 H7V7
- Ireland
Cosmo Pharmaceuticals Stock Performance
As of 13-Nov-2026, Cosmo Pharmaceuticals’s stock price is $68.42. Its current market cap is $1.18B with 17.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $68.42 | $70.28 | $58.74 - $166.08 | $1.18B | 17.2M | 33.2K | -$0.44 |
Cosmo Pharmaceuticals Financials Summary
As of 30-Jun-2026, Cosmo Pharmaceuticals has a trailing 12-month revenue of $120M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,281,593 | 1,985,918 | 999,658 | 924,037 |
| Revenue | 119,789 | 117,509 | 288,691 | 100,395 |
| EBITDA | 9,708 | 12,298 | 177,503 | 10,624 |
| Net Income | (7,410) | (4,070) | 144,175 | (11,668) |
| Total Assets | 791,872 | 719,615 | 673,013 | 581,490 |
| Total Debt | 4,926 | 5,010 | 2,290 | 2,033 |
Cosmo Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cosmo Pharmaceuticals Comparisons
Industry
Financing
Details
Cosmo Pharmaceuticals Competitors (44)
One of Cosmo Pharmaceuticals’s 44 competitors is Clinuvel Pharmaceuticals, a Corporation company based in Melbourne, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Clinuvel Pharmaceuticals | Corporation | Melbourne, Australia | ||||
| Brinton Pharmaceuticals | Private Equity-Backed | Pune, India | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Assertio Holdings | Formerly VC-backed | Lake Forest, IL | ||||
| Lilly USA | Corporation | Indianapolis, IN |
Cosmo Pharmaceuticals Patents
Cosmo Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2453243-A1 | Method for the diagnosis and/or follow up of the evolution of a tumor | Inactive | 11-Nov-2010 | ||
| WO-2012062831-A1 | Method for the diagnosis and/or follow up of the evolution of a tumor | Inactive | 11-Nov-2010 | ||
| US-11938141-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Active | 03-Aug-2007 | ||
| US-12337002-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Active | 03-Aug-2007 | ||
| US-20220280531-A1 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Active | 03-Aug-2007 | C07J5/0053 |
Cosmo Pharmaceuticals Signals
Cosmo Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cosmo Pharmaceuticals Investments & Acquisitions (8)
Cosmo Pharmaceuticals’s most recent deal was a Merger/Acquisition with Cassiopea for . The deal was made on 17-Dec-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cassiopea | 17-Dec-2021 | Merger/Acquisition | Drug Discovery | ||
| Acacia Pharma | 02-Jan-2020 | PIPE | Pharmaceuticals | ||
| Linkverse | 01-Mar-2019 | Secondary Transaction - Private | IT Consulting and Outsourcing | ||
| Linkverse | 01-Jan-2018 | Merger/Acquisition | IT Consulting and Outsourcing | ||
| Paion | 27-Jun-2016 | PIPE | Pharmaceuticals |
Cosmo Pharmaceuticals ESG
Risk Overview
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Cosmo Pharmaceuticals Exits (3)
Cosmo Pharmaceuticals’s most recent exit was on 02-Jan-2020 from Acacia Pharma. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Acacia Pharma | 02-Jan-2020 | Completed |
|
||
| Paion | 27-Jun-2016 | Completed |
|
||
| AIMM Therapeutics | 07-Jun-2013 | Later Stage VC | Completed |
Cosmo Pharmaceuticals Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cosmo Artificial Intelligence - Ai | Dublin, Ireland | 2015 | |
| Salix Pharmaceuticals (Dublin) | Dublin, Ireland | 2004 |
Cosmo Pharmaceuticals FAQs
-
When was Cosmo Pharmaceuticals founded?
Cosmo Pharmaceuticals was founded in 1997.
-
Where is Cosmo Pharmaceuticals headquartered?
Cosmo Pharmaceuticals is headquartered in Dublin, Ireland.
-
What is the size of Cosmo Pharmaceuticals?
Cosmo Pharmaceuticals has 347 total employees.
-
What industry is Cosmo Pharmaceuticals in?
Cosmo Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Cosmo Pharmaceuticals a private or public company?
Cosmo Pharmaceuticals is a Public company.
-
What is Cosmo Pharmaceuticals’s stock symbol?
The ticker symbol for Cosmo Pharmaceuticals is CMHC.
-
What is the current stock price of Cosmo Pharmaceuticals?
As of 13-Nov-2026 the stock price of Cosmo Pharmaceuticals is $68.42.
-
What is the current market cap of Cosmo Pharmaceuticals?
The current market capitalization of Cosmo Pharmaceuticals is $1.18B.
-
What is Cosmo Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Cosmo Pharmaceuticals is $120M.
-
Who are Cosmo Pharmaceuticals’s competitors?
Clinuvel Pharmaceuticals, Brinton Pharmaceuticals, Novartis, Assertio Holdings, and Lilly USA are some of the 44 competitors of Cosmo Pharmaceuticals.
-
What is Cosmo Pharmaceuticals’s annual earnings per share (EPS)?
Cosmo Pharmaceuticals’s EPS for 12 months was -$0.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process